Moreover, the long-term oral administration of MLE had a potential treatment effect on hyperglycemia, hyperinsulinemia, and metabolic profile alteration in the T2DM rat model by inhibiting DPP-IV and activating GLP-1 secretion. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.